Actinogen Medical Receives Independent DMC Positive Recommendation for Phase 2b/3 Alzheimer's Disease Trial, Shares Jump 10%
Actinogen Medical (ASX:ACW) received a positive recommendation from the XanaMIA phase 2b/3 Alzheimer's disease trial's independent data monitoring committee (DMC) to continue the trial without amendment, according to a Thursday Australian bourse filing.The committee comprises independent clinical and statistical experts who are not connected to the day-to-day conduct or analysis of the trial.The primary endpoint of the trial is the internationally recognized Clinical Dementia Rating scale-Sum of Boxes. Oral Xanamem 10 milligrams daily doses continue to demonstrate a promising safety profile in patients with mild to moderate Alzheimer's disease treated for up to 36 weeks in the trial, it added.Its shares jumped 10% in recent trading on Thursday.
